Acta Med. 2013, 56: 36-38
https://doi.org/10.14712/18059694.2014.37
EFFICACY OF TOPIRAMATE AS ADD-ON THERAPY IN TWO DIFFERENT TYPES OF PROGRESSIVE MYOCLONIC EPILEPSY
References
1. AE. Molecular background of progressive myoclonus epilepsy. EMBO J. 2003; 15; 22(14): 3473–3478.
<https://doi.org/10.1093/emboj/cdg338>
<PubMed>
2. Neubauer BA. Progressive and Infantile Myoclonic Epilepsies. In: Wyllie E, ed. The Treatment of Epilepsy: Principles and Practice. (5th ed.) Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. 2011; 269–279.
3. E, Baykan B, Gürses C, et al. Add-on therapy with topiramate in progressive myoclonic epilepsy. Epilepsy Behav. 2005; 6(2): 260–263.
<https://doi.org/10.1016/j.yebeh.2004.11.014>
4. R. Topiramate as a new antiepileptic drug in epileptic children in Iran. Indian J Pediatr. 2006; 73(12): 1073–1075.
<https://doi.org/10.1007/BF02763047>
5. A, Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996; 24: 73–77.
<https://doi.org/10.1016/0920-1211(95)00105-0>
6. HS. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia 1997; 38(suppl 1): 9–17.
<https://doi.org/10.1111/j.1528-1157.1997.tb04523.x>
7. V, Montouris GD, Ritter F, et al. A randomized, placebo controlled study of topiramate in primary generalized tonic-clonic seizures: Topiramate YTC Study Group. Neurology. 1999; 52: 1330–1337.
<https://doi.org/10.1212/WNL.52.7.1330>
8. LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia. 2000; 4: 977–980.
<https://doi.org/10.1111/j.1528-1157.2000.tb00282.x>
9. C, Dupont S, Leguern E, Adam C, Baulac M. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology. 2004; 24; 62(4): 640–643.
<https://doi.org/10.1212/01.WNL.0000110193.78872.DD>
10. PJ, Baxendale SA, Duncan JS, Sander JW. Effects of topiramate on cognitive function. J Neurol Neurosurg Psychiatry 2000; 69: 636–641.
<https://doi.org/10.1136/jnnp.69.5.636>
<PubMed>
11. RP, Gardocki JF, Streeter AJ, et al. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia 2000; 41(suppl. 1): 3–9.
<https://doi.org/10.1111/j.1528-1157.2000.tb02163.x>
